<DOC>
	<DOCNO>NCT01099748</DOCNO>
	<brief_summary>The objective study estimate effect lersivirine pharmacokinetics R-methadone S-methadone investigate safety tolerability lersivirine co-administered methadone . Symptoms methadone withdrawal also assess .</brief_summary>
	<brief_title>Estimate The Effect Of Lersivirine On The Pharmacokinetics Of S- And R-Methadone</brief_title>
	<detailed_description />
	<mesh_term>Methadone</mesh_term>
	<criteria>Healthy male and/or female subject ( Healthy define clinically relevant abnormality identify detailed medical history except drug abuse ) , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) 17.5 35.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Receiving stable methadone maintenance treatment least 3 month ( dose range 50150 mg QD ) . Subjects therapy Hepatitis B and/or Hepatitis C ; Evidence impair liver function ( ie , AST and/or ALT great 3 time upper limit normal , total bilirubin &gt; 1.5 time upper limit normal , albumin &lt; 3.5 g/dL ) . 12lead ECG demonstrate QTc &gt; 450 msec male QTc &gt; 470 msec female clinically significant abnormality screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>lersivirine</keyword>
	<keyword>methadone</keyword>
</DOC>